Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 83,839 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: therapy Clear all
Terminated Not applicable Interventional

Montelukast Added to Standard Therapy for Acute Asthma in Children Age 6-14 Years

NCT00353184
View directory record Official record
Conditions
Asthma
Interventions
Montelukast 5-mg orally added to standard therapy
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Years to 14 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 24, 2010 · Synced Oct 21, 2026, 10:43 PM EDT
Withdrawn Phase 1 Interventional

Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas

NCT04952584
View directory record Official record
Conditions
Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma
Interventions
CD30.CAR-EBVST cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2040
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 21, 2026, 10:43 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris

NCT00829049
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Cream 0.1%, Adapalene
Drug
Lead sponsor
Allergan
Industry
Eligibility
12 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2012 · Synced Oct 21, 2026, 10:43 PM EDT
Active, not recruiting Not applicable Interventional

Acceptability of Mobile Applications (Apps) to Enhance Smoking Cessation in a Clinical Tobacco Treatment Program - A Pilot Study

NCT05038852
View directory record Official record
Conditions
Smoking Cessation, Tobacco
Interventions
smartphone applications
Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 21, 2026, 10:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase 2, Open Label, Pharmacokinetic (PK) Study of TLC599 in Subjects With Osteoarthritis of the Knee

NCT03754049
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
TLC599, DSP
Drug
Lead sponsor
Taiwan Liposome Company
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • Miami, Florida • Charleston, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 21, 2026, 10:43 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Weight Loss, Blood Sugar and Blood Lipid Effects of Tetrahydrocannabivarin (THCV) Impregnated Mucoadhesive Strips

NCT05574049
View directory record Official record
Conditions
Metabolic Syndrome, Morbid Obesity, Hypercholesterolemia, Hyperglycemia
Interventions
Tetrahydrocannabivarin, Placebo
Drug · Other
Lead sponsor
Medical Life Care Planners, LLC
Other
Eligibility
18 Years to 100 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 21, 2026, 10:43 PM EDT
Completed Not applicable Interventional Results available

Mechanisms of Specific Trunk Exercises in Low Back Pain

NCT01362049
View directory record Official record
Conditions
Low Back Pain
Interventions
Physical Therapy rehabilitation: Stabilization exercises., Physical Therapy rehabilitation. Movement System Impairment (MSI) classification based exercise
Other
Lead sponsor
University of Vermont
Other
Eligibility
21 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 21, 2026, 10:43 PM EDT
Completed Phase 1 Interventional

Biological Therapy in Treating Patients With Metastatic Melanoma

NCT00045149
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin, therapeutic tumor infiltrating lymphocytes
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 7, 2010 · Synced Oct 21, 2026, 10:43 PM EDT
Not listed Phase 2 Interventional

Safety and Effectiveness of the Drug DPC 083 in Combination With Nucleoside Analogue Reverse Transcriptase Inhibitors in HIV-1-Infected Patients Who Are Failing Treatment With Nonnucleoside Reverse Transcriptase Inhibitors

NCT00007449
View directory record Official record
Conditions
HIV Infections
Interventions
DPC 083
Drug
Lead sponsor
Dupont Applied Biosciences
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Los Angeles, California • Newport Beach, California • Bradenton, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 10:43 PM EDT
Terminated Not applicable Interventional Results available

The Effect of Irrisept for Irrigation of Skin and Soft Tissue Infections (Irrisept USF Study)

NCT01076049
View directory record Official record
Conditions
Skin and Soft Tissue Infections, Abscess
Interventions
Standard of Care (SoC), Irrisept Delivery System
Device
Lead sponsor
Irrimax Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 21, 2026, 10:43 PM EDT
Completed Phase 2 Interventional Results available

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

NCT00728949
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
IMC-A12 (cixutumumab), tamoxifen, Anastrozole, Letrozole, Exemestane, Fulvestrant
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
9
States / cities
Scottsdale, Arizona • Chicago, Illinois • Westwood, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 21, 2026, 10:43 PM EDT
Completed Not applicable Interventional

A Whole Food Plant Diet and Its Lipidemic Effects on Primary Prevention in a Free-range Population

NCT03523247
View directory record Official record
Conditions
Diet Modification, Cardiology
Interventions
whole food, plant based diet
Behavioral
Lead sponsor
Lancaster General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 21, 2026, 10:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Impact of Fitness on Vascular Dysfunction in Adolescents With Type 1 Diabetes

NCT01337947
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Definity microbubbles
Drug
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 18 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Oct 21, 2026, 10:43 PM EDT
Not yet recruiting Phase 3 Interventional

A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

NCT07733947
View directory record Official record
Conditions
Subcutaneous Fat
Interventions
CBL-514 Injection, 0.9 % sodium chloride
Drug
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 10:43 PM EDT
Withdrawn Phase 2 Interventional

Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer

NCT03340558
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Atezolizumab, Cobimetinib
Biological · Drug
Lead sponsor
Niharika Mettu
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 21, 2026, 10:43 PM EDT
Recruiting Not applicable Interventional

Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer

NCT06698458
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
Interventions
Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Device
Lead sponsor
Alpha Tau Medical LTD.
Industry
Eligibility
18 Years to 120 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
13
States / cities
Gilbert, Arizona • Goodyear, Arizona • Scottsdale, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 21, 2026, 10:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Fentanyl Transdermal System (JNJ-35685-AAA-G021) Compared With DURAGESIC Fentanyl Transdermal Patch in Healthy Participants

NCT02617758
View directory record Official record
Conditions
Healthy
Interventions
Fentanyl
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 21, 2026, 10:43 PM EDT
Recruiting Early Phase 1 Interventional

Implantable Microdevice In Primary Brain Tumors

NCT04135807
View directory record Official record
Conditions
Grade II Glioma, Grade III Glioma, Grade IV Glioma, Astrocytoma, Oligodendroglioma of Brain, Anaplastic Astrocytoma of Brain, Anaplastic Oligodendroglioma, Glioblastoma
Interventions
Microdevice
Combination Product
Lead sponsor
Oliver Jonas
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 10:43 PM EDT
Terminated Phase 1 Interventional

Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL

NCT01728207
View directory record Official record
Conditions
Non-hodgkin's Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
IMMU-114
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Newark, Delaware • Savannah, Georgia • Goshen, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 21, 2026, 10:43 PM EDT
Terminated Early Phase 1 Interventional

Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)

NCT01337492
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Nexavar
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 21, 2012 · Synced Oct 21, 2026, 10:43 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

NCT03899792
View directory record Official record
Conditions
Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer, Soft Tissue Sarcoma
Interventions
Selpercatinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 21, 2026, 10:43 PM EDT
Completed Phase 3 Interventional

Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

NCT00482092
View directory record Official record
Conditions
Crohn's Disease
Interventions
Prochymal®, Placebo
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
47
States / cities
Los Angeles, California • San Francisco, California • Wheat Ridge, Colorado + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 21, 2026, 10:43 PM EDT
Recruiting Phase 2 Interventional

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

NCT06855771
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
BMS-986504, Izalontamab Brengitecan
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
10
States / cities
Anchorage, Alaska • Boston, Massachusetts • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 21, 2026, 10:43 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

NCT06467344
View directory record Official record
Conditions
Stargardt Disease, Cone Rod Dystrophy, Juvenile Macular Degeneration, Stargardt Disease 1
Interventions
ACDN-01
Drug
Lead sponsor
Ascidian Therapeutics, Inc
Industry
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
11
States / cities
San Francisco, California • Gainesville, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 21, 2026, 10:43 PM EDT